0.05Open0.05Pre Close0 Volume11 Open Interest7.50Strike Price0.00Turnover166.18%IV48.62%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0224Delta0.0102Gamma290.00Leverage Ratio-0.0078Theta-0.0002Rho-6.50Eff Leverage0.0017Vega
Neurogene Stock Discussion
Revolutionary Gene Therapy Technology Successfully Controls Rett Syndrome Treatment in Major Study
Neurogene's $312M War Chest Fuels Promising Rett Syndrome Treatment Progress
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet